Updates are available Correction dated 2025-03-26

Article History

Received: 2 December 2024

Accepted: 18 February 2025

First Online: 6 March 2025

Change Date: 22 March 2025

Change Type: Update

Change Details: The original online version of this article was revised:

Change Details: In this article, the order in which the authors appeared in the author list was incorrectly given as

Change Details: Charlotte Beaudart^1,2, Nicola Veronese^1,3, Jonathan Douxfils^4,5,6, Jotheeswaran Amuthavalli Thiyagarajan⁷, Francesco Bolzetta⁸, Paolo Albanese⁸, Gianpaolo Voltan⁸, Majed Alokail⁹, Nicholas C. Harvey^1,10, Nicholas R. Fuggle^1,10, René Rizzoli^1,12, Jean-Yves Reginster^1,9 where it should have been

Change Details: Charlotte Beaudart^1,2, Nicola Veronese^1,3, Jonathan Douxfils^4,5,6, Jotheeswaran Amuthavalli Thiyagarajan⁷, Francesco Bolzetta⁸, Paolo Albanese⁸, Gianpaolo Voltan⁸, Majed Alokail⁹, Nicholas C. Harvey^1,10, Nicholas R. Fuggle^1,10, Olivier Bruyère^1,11, René Rizzoli^1,12, Jean-Yves Reginster^1,9.

Change Details: In this article the affiliation '¹¹ Research Unit in Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium.' for Author Olivier Bruyère was missing.

Change Details: The original article has been corrected.

Change Date: 26 March 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00198-025-07452-x

Declarations

:

: The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.

: C.B. reports personal speaker fees from Nutricia outside the submitted work. N.V. reports personal honoraria from IBSA, Mylan, Nestlè, and Viatris, all outside the submitted work. J.D. reports personal fees from Daiichi-Sankyo, Diagnostica Stago, Estetra, Gedeon Richter, GyneBio Pharma, Mithra Pharmaceuticals, Neuralis, Norgine, Roche, Roche Diagnostics, Technoclone, Werfen, and YHLO, all outside the submitted work. N.C.H. declares that he has received personal fees, consultancy, lecture fees, and/or honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, Theramex, and Internis Pharma, outside the submitted work. N.R.F. declares that he has received travel bursaries from Eli Lilly and Pfizer and speaker’s fees from UCB and Viatris, outside the submitted work. R.R. declares that he has received fees as a speaker or consultant for Abiogen, Effryx, Nestlé, ObsEva, and Theramex, outside the submitted work. J-Y.R. declares that he has received consulting fees or has been on paid advisory boards for IBSA-Genevrier, Viatris, Radius Health, Rejuvenate Biomed, Celltrion, Promedius, and Theramex; received lecture fees when speaking at the invitation of the sponsor for IBSA-Genevrier, Theramex, and Viatris; and received grant support from IBSA-Genevrier, Viatris, Radius Health, and TRB, all through institutions and outside the submitted work. Other authors did not report any conflicts of interest in relation with this work.